I

Three decisions, and the hour is the smallest.

The question people ask about NMN is almost always the hour. Morning or evening. With coffee or before it. The question the published record is actually equipped to answer is a different one, and it is worth separating the two before going further.

Human trials of NMN have been built around three variables. The amount taken each day, which in the published work runs from 100 mg to roughly 1,200 mg. The duration, which runs from a single administration to twelve weeks and beyond. And the schedule, which in most protocols is simply once daily, in the morning, held constant so that it does not become a variable at all.

That last point matters. In the majority of these studies the hour was not being tested. It was being standardised, so that everyone in the trial did the same thing and the measurement stayed clean. A reader who takes morning dosing from the literature as a finding is reading a design decision as a result.

The table below sets out what the protocols actually specified, which is a more honest starting point than any rule of thumb.

II

The circadian argument, and its limits.

The case for the morning is not arbitrary. It comes from a well established line of work on the salvage pathway, the route by which cells recycle nicotinamide back into NAD+. The rate limiting enzyme in that route is nicotinamide phosphoribosyltransferase, usually shortened to NAMPT.

Two papers published in Science in 2009, by Nakahata and colleagues and by Ramsey and colleagues, described NAMPT as being under circadian clock control, with its expression oscillating across the twenty four hour cycle. That work was conducted in mice and in cultured cells, and the rhythm it describes has been reproduced many times since. It is one of the more durable findings in the field.

The inference people draw is straightforward: if the pathway runs on a daily rhythm, align the daily routine with it. That is a reasonable way to choose an hour. It is not the same as evidence that the hour changes anything in a person, and the distinction is worth keeping. A rhythm observed in an enzyme is a description of biology, not a prediction about a capsule.

So the morning convention has a rationale behind it and very little direct human comparison. Those two facts sit together more comfortably than most writing on the subject admits.

III

The question has been asked once.

One published trial has put the two windows side by side. Kim and colleagues, writing in Nutrients in 2022, randomised 108 adults aged 65 and over to 250 mg of NMN or a placebo, taken either before noon or after 18:00, for twelve weeks.

That is the whole of the direct comparison in the human literature: one trial, one age group, one amount, one duration, one population. Whatever such a study reports, a single trial of that shape is a starting point for a question rather than a close to it.

It is also worth noticing what the design implies. The researchers thought the hour was worth isolating, which tells you the field considers it an open question. Open questions are not the same as settled ones, and a reader choosing a routine today is choosing without a verdict.

The sensible conclusion is the unglamorous one. Fix the amount and the duration first, because those are the variables the literature has characterised. Then choose an hour you can keep.

IV

Empty stomach, breakfast, or split in two.

The fasted protocol that appears so often in the literature deserves the same reading as the morning convention. When Irie and colleagues gave single administrations at 09:00 after an overnight fast, the fast was there to keep the measurement clean. A standardised stomach makes plasma readings comparable between participants. It was a laboratory condition, not a daily instruction.

Later protocols loosened it. Several specified before breakfast, others simply once daily without conditioning on food at all, which is closer to how anything is actually taken at home. Both appear in the published record, and nothing in that record establishes a requirement either way.

The split schedule is the third pattern. At least one twelve week trial published in Frontiers in Nutrition divided a 250 mg daily total into 125 mg in the morning and 125 mg in the evening. It is a legitimate design that appears in the literature, and it is a reminder that once daily is a convention rather than a rule handed down.

For a reader, the practical translation is permissive. The protocols differ on food and on splitting, which is a reasonable sign that neither is the decisive variable. What they rarely differ on is that the schedule, whatever it was, held steady for weeks.

V

The methyl donor question.

A second scheduling question sits beside the first, and it is worth stating accurately because it is frequently overstated. Nicotinamide that the body does not route back through the salvage pathway can be methylated by the enzyme nicotinamide N-methyltransferase, a reaction that uses S-adenosylmethionine as the methyl donor.

That chemistry is why some formulas pair NMN with betaine, also written as trimethylglycine or TMG, which is a dietary methyl donor. The pairing is a formulation decision taken on mechanistic grounds.

What has not been established in human research is that the pairing is necessary, or at what intake it would become relevant. The mechanism is real and the requirement is not demonstrated, and those are two separate statements that often get printed as one. Anyone weighing it should raise it with a qualified healthcare professional rather than settle it from a diagram.

VI

Settled, and unsettled.

What is settled is the structure. NAD+ is a coenzyme of very wide involvement. The salvage pathway is the principal route of its turnover. NAMPT is the rate limiting step in that route and its expression has been described as rhythmic across the day. NMN sits one step from NAD+ within that pathway. None of this is seriously disputed.

What is unsettled is the hour. The direct human comparison amounts to a single trial in a single age group, and the circadian case, however elegant, is an inference drawn across species and across the gap between an enzyme and a routine. Anyone who tells you the question is closed is telling you more than the record supports.

The practical position follows from that. Choose an amount within the range the published protocols have used. Hold it for the kind of period those protocols ran, which is weeks rather than days. Attach it to a fixed point in the day that already exists in your routine, because an hour you keep is worth more than an hour you argue for. Research described here was conducted independently and did not involve any specific Codeage product.

And take the question itself to a qualified healthcare professional, who can consider it alongside everything else a page cannot see.

VII

Where this fits.

NMN sits in Cellular Longevity, the third pillar of The Longevity Code. A pillar is a location within a framework. It describes a category, and it describes nothing about an outcome for any reader.

The house position on timing is the one set out above. The amount and the duration are the decisions the published record can speak to. The hour is a decision about routine, and a routine is kept or broken on whether it is easy, not on whether it is ideal.

Nothing on this page is advice to begin, stop or change anything, and nothing on it replaces a conversation with a qualified healthcare professional.